JADPRO Live 2023: Focus on Multiple Myeloma
This section of coverage from JADPRO Live 2023, the Annual APSHO Meeting focuses on the most important meeting news on multiple myeloma for oncology nurses. The meeting, which ran from November 9-12, 2023, in Orlando, Florida, featured panel discussions, abstracts, posters, and education sessions on multiple myeloma for oncology nurses and advanced practitioners.
Speakers from the JADPRO Live session on myeloma share what they hope to see happen in the future.
Rachid Baz, MD, and Elizabeth Finley-Oliver, MSN, ARNP, AGNP-BC, delivered a presentation on the topic at JADPRO Live 2023.
Patients with relapsed or refractory multiple myeloma are at an increased risk for severe infections.
Researchers conducted a pooled analysis of the MagnetisMM studies.
Nurses involved with the MajesTEC-1 study recommended several practices for infection monitoring and management.
The survey received responses from 100 patients with multiple myeloma and 200 APPs who treat patients with the disease.
Patient and provider surveys can be "useful tools for understanding patient interest and barriers" in the program.
Anemia, a common complication of multiple myeloma, can be evaluated outside of an in-person setting.
There were 3 top reasons why patients contacted the program for assistance.
In addition, deepened or sustained responses were also seen in patients who went from weekly to biweekly elranatamab.
The Right Track educational program, created by The Multiple Myeloma Research Foundation, includes 3 critical components.
Dexamethasone can be safely stopped at 6 months in patients with multiple myeloma who have started combination therapies.
The median time to switch from weekly to biweekly or monthly dosing was 11.3 months.
Advertisement
Advertisement
